|
US5969145A
(en)
*
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
|
DK1367057T3
(da)
|
1996-11-18 |
2009-01-19 |
Biotechnolog Forschung Gmbh |
Epothiloner E og F
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
WO1999001124A1
(en)
|
1996-12-03 |
1999-01-14 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6660758B1
(en)
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6605599B1
(en)
*
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
|
ES2290993T3
(es)
|
1997-08-09 |
2008-02-16 |
Bayer Schering Pharma Aktiengesellschaft |
Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
|
|
US6365749B1
(en)
*
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
|
US6302838B1
(en)
|
1998-02-25 |
2001-10-16 |
Novartis Ag |
Cancer treatment with epothilones
|
|
FR2775187B1
(fr)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
|
US6399638B1
(en)
*
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
|
US6498257B1
(en)
*
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
|
NZ511722A
(en)
|
1998-11-20 |
2004-05-28 |
Kosan Biosciences Inc |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
|
CN1122668C
(zh)
|
1998-12-22 |
2003-10-01 |
诺瓦提斯公司 |
环氧噻酮衍生物，其制备方法及其药物组合物
|
|
US6780620B1
(en)
*
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
|
IL144370A0
(en)
*
|
1999-02-11 |
2002-05-23 |
Schering Ag |
Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
|
AU772750C
(en)
*
|
1999-04-30 |
2005-02-24 |
Schering Aktiengesellschaft |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
|
DE10020899A1
(de)
*
|
2000-04-20 |
2001-10-25 |
Schering Ag |
9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
|
|
US6489314B1
(en)
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
AU2001266583A1
(en)
*
|
2000-05-26 |
2001-12-11 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
UA75365C2
(en)
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
|
EP1414384A4
(en)
|
2000-10-13 |
2005-07-27 |
Univ Mississippi |
SYNTHESIS OF EPOTHILONES AND TRANSFORMATION ANALOGUE
|
|
HU229349B1
(en)
|
2001-01-25 |
2013-11-28 |
Bristol Myers Squibb Co |
Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
|
|
AU2002245296B2
(en)
*
|
2001-01-25 |
2006-12-21 |
Bristol-Myers Squibb Company |
Methods of administering epothilone analogs for the treatment of cancer
|
|
IL156580A0
(en)
*
|
2001-01-25 |
2004-01-04 |
Bristol Myers Squibb Co |
A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
|
|
NZ526871A
(en)
|
2001-01-25 |
2006-01-27 |
Bristol Myers Squibb Co |
Pharmaceutical dosage forms of epothilones for oral administration
|
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
PL363363A1
(en)
|
2001-02-20 |
2004-11-15 |
Bristol-Myers Squibb Company |
Epothilone derivatives for the treatment of refractory tumors
|
|
BR0207487A
(pt)
|
2001-02-20 |
2004-08-10 |
Brystol Myers Squibb Company |
Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
|
|
KR20030084952A
(ko)
|
2001-02-27 |
2003-11-01 |
게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) |
에포틸론의 분해 및 에티닐 치환된 에포틸론
|
|
WO2002072085A1
(en)
*
|
2001-03-14 |
2002-09-19 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
MXPA03010909A
(es)
|
2001-06-01 |
2004-02-17 |
Bristol Myers Squibb Co |
Derivados de epotilona.
|
|
TWI315982B
(en)
*
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
|
AU2003235761A1
(en)
|
2002-01-14 |
2003-07-24 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
|
AU2003218107A1
(en)
*
|
2002-03-12 |
2003-09-29 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
|
SI1483251T1
(sl)
|
2002-03-12 |
2010-03-31 |
Bristol Myers Squibb Co |
C cian epotilonski derivati
|
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
WO2003105828A1
(en)
|
2002-06-14 |
2003-12-24 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
DE10232094A1
(de)
*
|
2002-07-15 |
2004-02-05 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
5-Thiaepothilone und 15-disubstituierte Epothilone
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
DE60330407D1
(de)
*
|
2002-08-23 |
2010-01-14 |
Sloan Kettering Inst Cancer |
Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
|
|
BRPI0314133A8
(pt)
|
2002-09-23 |
2017-09-19 |
Bristol Myers Squibb Co |
Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
|
|
AU2003264822A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Dana-Farber Cancer Institute Inc |
Epothilone derivatives for the treatment of multiple myeloma
|
|
US7632858B2
(en)
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
US7645782B2
(en)
*
|
2002-11-28 |
2010-01-12 |
Wolfgang Richter |
Thia-epothilone derivatives for the treatment of cancer
|
|
WO2004052361A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Novartis Ag |
Microtubule stabilisers for treating stenosis in stents
|
|
GB0230024D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Novartis Ag |
Organic compounds
|
|
CN101177425B
(zh)
*
|
2003-01-28 |
2012-07-18 |
北京华昊中天生物技术有限公司 |
一类新型埃坡霉素化合物及其制备方法和用途
|
|
ES2349532T3
(es)
|
2003-02-06 |
2011-01-04 |
Bristol-Myers Squibb Company |
Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
|
|
GB0305928D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AU2008200555C1
(en)
*
|
2003-03-14 |
2011-12-15 |
Novartis Ag |
Treatment of proliferative diseases with epothilone derivatives and radiation
|
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
DE10344882A1
(de)
*
|
2003-09-26 |
2005-04-21 |
Morphochem Ag Komb Chemie |
Neue Makrocyclen zur Behandlung von Krebserkrankungen
|
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
|
WO2005054429A2
(en)
*
|
2003-11-19 |
2005-06-16 |
The University Of Mississippi |
Synthesis of the c1-c6 keto-acid synthon of the epothilones
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
EP1559447A1
(en)
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
WO2006017761A2
(en)
*
|
2004-08-05 |
2006-02-16 |
Emory University |
Epothilone analogues as therapeutic agents
|
|
EP1640004A1
(en)
*
|
2004-09-24 |
2006-03-29 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of bone metastases and bone tumors or cancers
|
|
AR052142A1
(es)
|
2004-11-18 |
2007-03-07 |
Bristol Myers Squibb Co |
Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
|
|
EP1824458A1
(en)
*
|
2004-11-18 |
2007-08-29 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
|
|
US20060121511A1
(en)
|
2004-11-30 |
2006-06-08 |
Hyerim Lee |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
|
EP2634252B1
(en)
|
2005-02-11 |
2018-12-19 |
University of Southern California |
Method of expressing proteins with disulfide bridges
|
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US20110104664A1
(en)
|
2006-03-31 |
2011-05-05 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
|
|
US8008256B2
(en)
*
|
2006-05-01 |
2011-08-30 |
University Of Southern California |
Combination therapy for treatment of cancer
|
|
AU2007250443B2
(en)
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
MX2009005849A
(es)
|
2006-12-04 |
2009-08-12 |
Univ Illinois |
Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
|
|
KR20090114414A
(ko)
|
2007-02-08 |
2009-11-03 |
더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 |
쿠프레독신으로 암을 예방하는 조성물과 방법
|
|
WO2008147941A1
(en)
|
2007-05-25 |
2008-12-04 |
Bristol-Myers Squibb Company |
Processes for making epothilone compounds and analogs
|
|
US20090076099A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ixabepilone
|
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
|
US8449886B2
(en)
*
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
CA2722371C
(en)
*
|
2008-04-24 |
2016-06-21 |
Bristol-Myers Squibb Company |
Use of epothelone d in treating tau-associated diseases including alzheimer's disease
|
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
|
JP4500951B1
(ja)
*
|
2009-08-07 |
2010-07-14 |
学校法人神戸学院 |
Ｄｎａ合成酵素阻害剤
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
PH12012500901A1
(en)
|
2009-11-05 |
2016-08-05 |
Rhizen Pharmaceuticals Sa |
Novel benzopyran kinase modulators
|
|
WO2011098904A1
(en)
|
2010-02-12 |
2011-08-18 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
AU2011255647A1
(en)
|
2010-05-18 |
2012-11-15 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
|
KR20130086534A
(ko)
|
2010-06-01 |
2013-08-02 |
플러스 케미칼스, 에스.에이. |
익사베필론의 고체 형태
|
|
CN101906099A
(zh)
*
|
2010-07-16 |
2010-12-08 |
泰州市今朝伟业精细化工有限公司 |
一种埃博霉素d-内酰胺衍生物化学合成方法
|
|
CN103442737B
(zh)
|
2011-01-20 |
2017-03-29 |
得克萨斯系统大学董事会 |
Mri标记、递送和提取系统及其制造方法和用途
|
|
WO2012135278A2
(en)
*
|
2011-04-01 |
2012-10-04 |
The Research Foundation Of State University Of New York |
Olefin-triggered acid amplifiers
|
|
KR20140033027A
(ko)
*
|
2011-04-01 |
2014-03-17 |
더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 |
안정화된 산 증폭제
|
|
HRP20190128T1
(hr)
|
2011-05-04 |
2019-03-08 |
Rhizen Pharmaceuticals S.A. |
Novi spojevi kao modulatori protein kinaza
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
|
WO2013008091A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Xellia Pharmaceuticals Aps |
Manufacturing of epothilone derivatives and the use thereof
|
|
EP2567825B1
(en)
|
2011-09-12 |
2014-04-02 |
Agfa-Gevaert |
Colour laser marking methods of security document precursors
|
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
|
US9764038B2
(en)
|
2011-12-23 |
2017-09-19 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
EP2831073B1
(en)
|
2012-03-30 |
2020-12-09 |
Rhizen Pharmaceuticals S.A. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
US10036010B2
(en)
|
2012-11-09 |
2018-07-31 |
Innate Pharma |
Recognition tags for TGase-mediated conjugation
|
|
CN104768962B
(zh)
|
2012-11-17 |
2017-04-05 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
US9309259B2
(en)
|
2013-03-08 |
2016-04-12 |
Scinopharm Taiwan, Ltd. |
Process for ixabepilone, and intermediates thereof
|
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
US10201623B2
(en)
|
2013-03-15 |
2019-02-12 |
Memorial Sloan Kettering Cancer Center |
HSP90-targeted cardiac imaging and therapy
|
|
HK1219879A1
(zh)
|
2013-06-11 |
2017-04-21 |
Bayer Pharma Aktiengesellschaft |
用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
ポリペプチドの酵素的結合
|
|
EA032231B1
(ru)
|
2013-10-11 |
2019-04-30 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
|
CA2927022C
(en)
|
2013-10-11 |
2018-08-21 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
|
US10341459B2
(en)
|
2015-09-18 |
2019-07-02 |
International Business Machines Corporation |
Personalized content and services based on profile information
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
JP7320458B2
(ja)
|
2017-06-22 |
2023-08-03 |
メルサナ セラピューティクス インコーポレイテッド |
薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|
|
ES2975330T3
(es)
|
2018-05-04 |
2024-07-04 |
Tagworks Pharmaceuticals B V |
Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
|
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
EP4382129A3
(en)
|
2019-06-17 |
2024-07-03 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
BR112022013685A2
(pt)
|
2020-01-10 |
2022-09-06 |
R Pharm Us Operating Llc |
Composições de ixabepilona
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
JP2024532537A
(ja)
|
2021-09-06 |
2024-09-05 |
ヴェラクサ バイオテック ゲーエムベーハー |
真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
|
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
ES3039688T3
(en)
|
2021-11-25 |
2025-10-23 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
KR20240119102A
(ko)
|
2021-12-08 |
2024-08-06 |
유럽피안 몰레큘러 바이올로지 래보러토리 |
표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
|
|
EP4372000A3
(en)
|
2022-02-15 |
2024-07-17 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
|
JP2025524728A
(ja)
|
2022-07-15 |
2025-07-30 |
フィアン セラピューティクス エルティーディー |
抗体－薬物複合体
|
|
IL320221A
(en)
|
2022-10-12 |
2025-06-01 |
Tagworks Pharmaceuticals B V |
Strained bicyclo-nonanes
|
|
CN120569216A
(zh)
|
2023-01-20 |
2025-08-29 |
巴斯夫欧洲公司 |
稳定型生物聚合物组合物、其制造和用途
|
|
KR20250169530A
(ko)
|
2023-03-10 |
2025-12-03 |
태그웍스 파마슈티컬스 비.브이. |
개선된 t-링커를 갖는 트랜스-사이클로옥텐
|
|
AU2024300552A1
(en)
|
2023-07-27 |
2026-01-29 |
Veraxa Biotech Gmbh |
Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
|
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025174248A1
(en)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctenes with "or gate" release
|
|
WO2026043376A1
(en)
|
2024-08-22 |
2026-02-26 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctene formulations
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026078060A1
(en)
|
2024-10-08 |
2026-04-16 |
Basf Se |
Tocopherol alkoxylates for biopolymer stabilization
|